% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@INBOOK{Drzezga:911484,
author = {Drzezga, Alexander and Bischof, Gérard and Giehl, Kathrin
and Eimeren, Thilo van},
title = {{PET} and {SPECT} {I}maging of {N}eurodegenerative
{D}iseases},
address = {Amsterdam},
publisher = {Elsevier},
reportid = {FZJ-2022-04753},
pages = {1309-1334},
year = {2021},
note = {},
comment = {Molecular Imaging: Principles and Practice},
booktitle = {Molecular Imaging: Principles and
Practice},
abstract = {Today, a number of complementary molecular imaging methods
are at our disposal, which can make a relevant contribution
to early diagnosis, differential diagnosis, disease
monitoring, and follow-up of neurodegenerative diseases.
This includes long-established FDG-PET which provides
valuable information on location and extent of pathology and
has demonstrated great value for early diagnosis, short-term
prognosis, and for differential diagnosis of various
disorders on the basis of the endophenotype of disease.
Imaging of the dopaminergic system has proven value in the
workup of movement disorders. More recently introduced,
amyloid-PET for the first time allows in vivo diagnostic
assessment of a molecular neuropathology, most valuable for
verification or exclusion of Alzheimer disease (AD),
independent of the symptomatic appearance. Finally, new
tracers for tau-PET imaging may allow the assessment of
location, extent, and specific type of pathology, which may
hold great value for early and differential diagnosis of
neurodegeneration in the future.},
cin = {INM-2},
cid = {I:(DE-Juel1)INM-2-20090406},
pnm = {5252 - Brain Dysfunction and Plasticity (POF4-525) / 5253 -
Neuroimaging (POF4-525)},
pid = {G:(DE-HGF)POF4-5252 / G:(DE-HGF)POF4-5253},
typ = {PUB:(DE-HGF)7},
url = {https://juser.fz-juelich.de/record/911484},
}